Effect of Platelet-Rich Plasma and Platelet-Rich Fibrin in Melasma

Comparison of the effectiveness of two therapeutic methods: platelet rich plasma and Platelet Rich Fibrin in improving treatment resistant melasma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240822062839N3

Enrollment

Registered

2025-09-17

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention Group 1:One side of the participant’s face will receive intradermal injections of platelet-rich fibrin (PRF). The treatment consists of two sessions, one month apart. At e

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosis of melasma History of non-response to standard oral and topical melasma treatments Individuals aged over 15 years and under 60 years not pregnant or breastfeeding unwillingness to use standard oral and topical melasma treatments

Exclusion criteria

Exclusion criteria: Presence of any underlying disease or malignancy Receipt of any melasma treatment within the past 3 months History of receiving hormonal therapy

Design outcomes

Primary

Measure	Time frame
Modified Melasma Area and Severity Index (mMASI) score. Timepoint: The primary outcome (mMASI score) will be measured at baseline (before the first intervention) and at 4, 8, 12, and 24 weeks after the start of the intervention. Method of measurement: The primary outcome variable, mMASI score, will be measured through clinical examination by a dermatologist using standardized criteria for the modified Melasma Area and Severity Index. Assessments will be based on direct observation and standardized digital photographs taken under consistent lighting conditions.	—

Measure

Time frame

Modified Melasma Area and Severity Index (mMASI) score. Timepoint: The primary outcome (mMASI score) will be measured at baseline (before the first intervention) and at 4, 8, 12, and 24 weeks after the start of the intervention. Method of measurement: The primary outcome variable, mMASI score, will be measured through clinical examination by a dermatologist using standardized criteria for the modified Melasma Area and Severity Index. Assessments will be based on direct observation and standardized digital photographs taken under consistent lighting conditions.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Razmara Farzaghi

Mashhad University of Medical Sciences

razmarafarnaghim@mums.ac.ir+98 915 163 9946

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026